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ABSTRACT: Molecular docking is a powerful tool used in
drug discovery and structural biology for predicting the
structures of ligand−receptor complexes. However, the
accuracy of docking calculations can be limited by factors
such as the neglect of protein reorganization in the scoring
function; as a result, ligand screening can produce a high rate
of false positive hits. Although absolute binding free energy
methods still have diﬃculty in accurately rank-ordering
binders, we believe that they can be fruitfully employed to
distinguish binders from nonbinders and reduce the false
positive rate. Here we study a set of ligands that dock favorably
to a newly discovered, potentially allosteric site on the ﬂap of HIV-1 protease. Fragment binding to this site stabilizes a closed
form of protease, which could be exploited for the design of allosteric inhibitors. Twenty-three top-ranked protein−ligand
complexes from AutoDock were subject to the free energy screening using two methods, the recently developed binding energy
analysis method (BEDAM) and the standard double decoupling method (DDM). Free energy calculations correctly identiﬁed
most of the false positives (≥83%) and recovered all the conﬁrmed binders. The results show a gap averaging ≥3.7 kcal/mol,
separating the binders and the false positives. We present a formula that decomposes the binding free energy into contributions
from the receptor conformational macrostates, which provides insights into the roles of diﬀerent binding modes. Our binding
free energy component analysis further suggests that improving the treatment for the desolvation penalty associated with the
unfulﬁlled polar groups could reduce the rate of false positive hits in docking. The current study demonstrates that the
combination of docking with free energy methods can be very useful for more accurate ligand screening against valuable drug
targets.
■ INTRODUCTION
Molecular docking is widely used in rational drug discovery and
structural biology for predicting the most favorable pose and for
estimating the strength of ligand−receptor binding.1,2 In a
typical virtual screening application, a large library of
compounds is docked against a receptor target site to generate
plausible poses ranked by scoring functions. Such functions are
typically designed to have a simple form for computational
eﬃciency. While docking has matured into a powerful tool for
pharmaceutical research after decades of development,1−7 the
accuracy of docking calculations continues to be limited by
these relatively simple scoring functions which lack a complete
treatment of desolvation and receptor reorganization.8,9
Additionally, entropic factors are generally not captured well
by scoring based on a single structure.8,10 As a result, structure-
based ligand screening by docking often generates a large
number of false positive hits. As a recent example, Shoichet et
al.11 conducted a parallel study of docking and HTS to screen
197861 compounds against cruzain, a thiol protease with a
relatively rigid binding pocket. Among the top 0.1% of the
docking-ranked library, 97.5% of the hits were found to be false
positives.11
Binding free energy methods are based on statistical
mechanics and atomistic simulations and, in principle, can
Special Issue: William L. Jorgensen Festschrift
Received: June 26, 2014
Revised: September 3, 2014
Published: September 5, 2014
Article
pubs.acs.org/JPCB
© 2014 American Chemical Society 976 dx.doi.org/10.1021/jp506376z | J. Phys. Chem. B 2015, 119, 976−988
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
capture the desolvation, receptor reorganization, and entropic
eﬀects, which provides a less empirical route to the calculation
of ligand-binding aﬃnities.12,13 The methodology of free energy
perturbation for computing the relative and absolute free
energy of molecular association was pioneered by Jorgen-
sen,14,15 McCammon,16−18 and Kollman19−21 30 years ago.
Since then, advances in the methodology, energy functions, and
computer hardware have enabled free energy calculations to
play an increasingly important role in the study of biomolecular
recognition.22−38 Signiﬁcant progress has been made in recent
years in applying the free energy perturbation method (FEP) to
the discovery of highly potent drug molecules for pharmaceut-
ical research.31,39−41 While the accuracy of absolute binding free
energy methods is still constrained by the quality of the current
force ﬁelds and the extent of sampling, which makes it
challenging to rank-order binders with similar binding aﬃnities,
we believe that free energy methods can be fruitfully applied as
additional ﬁlters for docking to separate binders from
nonbinders. Because of the high computational cost associated
with free energy calculations, currently it is only practical to
perform such simulations on a relatively small set of top ligands
obtained from docking. While the calculation of the absolute
binding free energies of libraries containing thousands of
ligands is beyond the current technology, the use of free energy
methods to score the binding aﬃnity of hundreds of ligands to
their target receptor is now possible.8 In a recent study, we have
shown that the combined application of docking and free
energy methods resulted in a large improvement8 over docking
alone,42 which helps researchers to focus on the true binders
and prioritize synthetic chemistry eﬀorts more eﬀectively.
HIV-1 protease (PR) has been a major drug target for
antiviral therapy against AIDS.43 To date, a total of nine
protease inhibitors have been FDA-approved, all of which are
active site binders; they constitute a key component in the
highly active antiretroviral therapy (HAART) cocktails.
However, the eﬃcacy of these active-site inhibitors has been
reduced by the emergence of drug-resistance mutations. Novel
inhibition strategies targeting alternative, allosteric sites of PR
are needed to overcome the drug resistance mutations aﬀecting
active site inhibition. The active site of PR is covered by two
ﬂexible β-hairpin ﬂaps that control substrate access to the active
site cavity, and the mobility of the ﬂaps is crucial to the
enzymatic activity of PR.44−46 The ﬂaps of PR can exist in
diﬀerent conformations: most apo structures adopt a semiopen
conformation, whereas a closed conformation is favored when
the active site is occupied by a ligand.47,48 Using fragment
screening by X-ray crystallography, Perryman and Tiefenbrunn
and co-workers recently discovered a new binding site, named
the ﬂap binding site, located on top of the ﬂaps of PR (Figure
1).49−51 Fragment 1F1 (indole-6-carboxylic acid) binding to
this ﬂap site was found to stabilize the closed conformation of
PR, even in the absence of an active site ligand.50 This suggests
that ligand binding to the ﬂap site could potentially enhance the
binding aﬃnity of an active site inhibitor by reducing the
protein reorganization free energy cost associated with the
semiopen-to-closed transition.46 Tiefenbrunn et al. performed
docking to virtually screen a focused library of 2518
compounds selected for similar structural features against the
1F1 ﬂap binding site.50 41 top hits were selected for further
experimental screening, including cocrystallization. Out of these
41 top hits, only a small fraction of the fragments showed any
binding signal in various assays.
In this work, we perform binding free energy calculations on
a set of ligands that dock favorably to the ﬂap site of PR. The
structures of the protein−ligand complexes from AutoDock1,2
were used as the starting point for the free energy calculation.
Two free energy methods, the binding energy distribution
analysis method (BEDAM) and the double decoupling method
(DDM) were employed. While DDM25,52,53 is the standard
method for computing absolute binding free energy in explicit
solvent, the recently developed BEDAM54 method employs
Halmiltonian replica exchange in an implicit solvent model to
accelerate the sampling of the phase space. The calculations are
performed for 23 ligands, including 3 conﬁrmed actives, 8 likely
binders, and 12 false positives. A majority of the false positive
ligands chosen have more favorable docking score than that of
the true binders, which increases the challenge for the free
energy methods. Our calculations using each of the methods
correctly identiﬁed ≥83% of the false positives and recovered
all of the conﬁrmed binders. A gap averaging ≥3.7 kcal/mol in
the computed binding free energy is found between the binders
and false positives. Six out of eight likely binders are predicted
to bind at the ﬂap site, a prediction that requires further
conﬁrmation by NMR screening with site labeling. The free
energy simulations also revealed the diﬀerent binding modes
for certain binders carrying a carboxylate group. One of the
binding modes contains an intermolecular salt bridge between
Arg57 and the ligand carboxylate ion. In the other binding
mode, this intermolecular salt bridge is replaced by the
intramolecular salt bridge between Arg57 and Glu35. Free
energy calculations suggest that the intermolecular salt bridge
provides the largest contribution to the binding aﬃnity for 1F1.
Analysis of the free energy decomposition results revealed that
the main reason for the high false positive rate in docking could
be due to the presence of partially buried, unfulﬁlled polar
groups for which the high desolvation penalty is not adequately
captured by the scoring function. The free energy calculation
also provided insights into fragment optimization for potency
enhancement. This study provides further conﬁrmation of the
power of combining docking with free energy methods for
accurate ligand screening against pharmaceutical targets. The
main challenge in successfully applying this approach to ligand
screening is to be able to carry out a relatively large number of
absolute binding free energy calculations in a reliable,
automated, and rapid fashion.8,55
Figure 1. Crystal structure of HIV PR (pdb id: 3kfr) with its ﬂap site
occupied by the ligand 1F1 shown in green stick. The active site ligand
is removed from the ﬁgure for clarity.
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■ COMPUTATIONAL METHODS
Binding Energy Distribution Analysis Method
(BEDAM). In the BEDAM approach,54 which uses the OPLS
force ﬁeld56,57 and an implicit solvation model AGBNP2,58 the
standard binding free energy (ΔGb0) is computed using the
following hybrid eﬀective potential connecting the unbound (λ
= 0) and bound state (λ = 1)
λ= +λU r U r u r( ) ( ) ( )0 (1)
Here, the unbound state Hamiltonian U0(r) is the sum of the
eﬀective energies of a receptor A and a ligand B when the two
are fully decoupled from each other
= +U r U r U r( ) ( ) ( )0 A B (2)
And u(r) is the binding energy function, i.e. for each
conformation r = (rA,rB), u(r) is the diﬀerence in the eﬀective
energy between the complex and the two dissociated molecules
A and B:
= − −u r U r r U r U r( ) ( , ) ( ) ( )A B A B (3)
From eqs 1−3, it can be seen that, when λ goes from 0 to 1,
the Hamiltonian of the system changes from that of the
unbound state U0(r) to that of the fully coupled state U1(r) =
U(rA,rB). The binding free energy ΔGb is the free energy
diﬀerence between the two end states
∫Δ = − < > = −→ − −G kT kT P u uln e ln ( )e du kT u kT0 1 / 0 0 /
(4)
The integrand is a product of a steeply increasing function of
u, P0(u), and a steeply decreasing function e
−u/kT. Therefore, it
is necessary to calculate the favorable energy tail of the
distribution P0(u) accurately. To accomplish this, BEDAM
employs a Hamiltonian Replica Exchange λ-hopping strategy
(H-REM), in which the simulated systems at diﬀerent λ
periodically attempt to exchange their conﬁgurations through
MC moves. The use of H-REM has been shown to yield
superior conformational sampling and more rapid convergence
rates by allowing conformational transitions to occur at values
of λ at which they are most likely to occur and to be then
propagated to other states.54,59
In BEDAM, ΔG0→1 is computed using the multistate Bennett
acceptance ratio estimator (MBAR)60 ΔG0→1 = kT( f1̂ − f0̂),
from values of binding energy (u) sampled at a series of
intermediate λ values using molecular dynamics simulations.
Here fλ̂ is the MBAR dimensionless free energy deﬁned as the
negative of the logarithm of the partition function at an
intermediate λ, fλ̂ = −ln Zλ. The values of fλ̂ are obtained from
the self-consistent solution of the set of MBAR equations60
∑ ∑ λ
λ
̂ = −
−
∑ ̂ −= = =
f
u kT
N f u kT
ln
exp( / )
exp( / )i j
K
n
N
i jn
k
K
k k k jn1 1 1
j
(5)
Here fî = fλ̂i, ujn is the nth binding energy sampled at the
intermediate λj replica, K is the number of replicas, and Nj is the
number of samples in replica j. For the MBAR analysis, we
employed the code provided by John Chodera and Michael
Shirts (http://alchemistry.org).60
The standard binding free energy (ΔGb0) is then obtained
using
Δ = − + ΔG k T C V Glnb0 B 0 site b (6)
In this work, BEDAM simulations of the 23 ligand−PR
complexes were performed for 3 ns per replica (48 ns of total
simulation time per ligand). The systems were ﬁrst energy-
minimized and then gradually heated to 300 K in 75 ps and
equilibrated at 300 K for an additional 75 ps before the
production run.
Hamiltonian replica exchange simulations were conducted
using 16 lambdas: 0.0, 0.001, 0.002, 0.004, 0.006, 0.008, 0.01,
0.02, 0.04, 0.07, 0.1, 0.25, 0.4, 0.55, 0.75, and 1.0. The binding
site is deﬁned as a sphere with a radius of 2 Å from the center
of mass of residues 44, 46, 55, and 57 of chain B of the HIV-PR
dimer. The formation of the complex is deﬁned by the center of
the mass of the ligand being within the binding site sphere.
There are two equivalent binding sites on the HIV PR dimer. In
this study, the site on chain B is used in the simulation. The Cα
atoms of the receptor were restrained with a force constant of
2.0 kcal/mol/Å2. These atomic restraints are applied in the
BEDAM simulations in order to prevent the slow drift of the
structure which can occur over long times. During the
simulations, the structures were saved every picosecond. The
last 2 ns of data were used for analysis. Statistical uncertainties
were obtained by comparing the results computed using the
ﬁrst and second halves for the last 3 ns of each BEDAM
simulation.
The binding free energy can be expressed as the sum of the
reorganization free energy and the average binding energy,
Δ = Δ + ΔG E Gb0 b reorg0 (7)
As described in an earlier paper,61 this decomposition
corresponds to a hypothetical thermodynamic cycle in which
the unbound ligand and protein in solution are ﬁrst reorganized
to match those of the complex, and in a subsequent step,
interactions between the ligand and protein are turned on. The
ﬁrst step is associated with the reorganization free energy
(ΔGreorg0 ). The second step is accompanied by the change in the
eﬀective potential energy ΔEbind, which includes direct
noncovalent interactions (electrostatic and van der Waals) as
well as the net desolvation of the binding partners.54,61 ΔEbind is
computed from the average, ⟨u⟩1, of the binding energy
function in the ensemble of conformations of the complex in
the coupled state (λ = 1). ΔGreorg0 is computed from the
diﬀerence of the computed binding free energy and the average
binding energy:
Δ = Δ − < >G G ureorg0 b0 1 (8)
DDM Calculation. The double decoupling25,52,53 calcu-
lations in explicit solvent (TIP3P water model62 plus
counterions) were performed for the 23 ligands at 300 K to
estimate the binding free energies. The protein molecule is
modeled by the Amber ﬀ99sb-ILDN force ﬁeld,63 and the
ligands are described by the Amber GAFF64 parameters set.
The partial charges of the ligands are obtained using the AM1-
BCC method.65 A DDM calculation involves two legs of
simulation, in which a restrained ligand is gradually decoupled
from the receptor binding pocket or from the aqueous solution.
In each leg of the decoupling simulations, the Coulomb
interaction is turned oﬀ ﬁrst using 11 lambda windows, λ = 0.0,
0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0; the Lennard-
Jones interactions are then turned oﬀ in 17 lambda windows, λ
= 0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85,
0.9, 0.94, 0.985, and 1.0. The two decoupling free energies
ΔGgas*→complex and ΔGgas→water associated with the two legs of
The Journal of Physical Chemistry B Article
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the DDM cycle were determined using thermodynamic
integration (TI). The Hamiltonian derivative ⟨∂U/∂λ⟩λ at a
series of λ from 0 to 1 were collected and integrated to obtain
the free energy diﬀerence. The MD sampling at each λ were
performed using the GROMACS66,67 version 4.6.4 for 15 ns;
the last 10 ns was used for the calculation of binding free energy
using TI.
Umbrella Sampling. To calculate the PMF of the
intramolecular distance Glu35-Arg57 using umbrella sam-
pling,68 a series of MD simulations is performed using
GROMACS66,67 (version 4.6.4) on the apo PR with the
harmonic distance restraint between the CD atom of Glu35 and
CA atom of Arg57. The biasing potential in the ith simulation
window is Wi(r) = (1/2)ki(r − ri0)2, where ki is the force
constant, r is the reaction coordinate, and ri
0 is the reference
distance for the ith sampling window. The full range of the
reaction coordinate space is covered using 20 windows centered
at: ri
0 = 3.7, 4.0, 4.3, 4.6, 4.9, 5.2, 5.5, 5.8, 6.1, 6.4, 6.7, 7.0, 7.3,
7.6, 7.9, 8.2, 8.5, 8.8, 9.1, and 9.4 Å. A single force constant k =
2.4 kcal mol−1 Å−2 is used for all the sampling windows. In each
sampling window, an 11 ns MD simulation is performed,
starting from the last conformation of the previous sampling
window. The ﬁrst 1 ns is treated as equilibration, which allows
the system to adjust to the current umbrella potential. The last
10 ns of sampling data are used for the calculation of PMF. The
biased probability distributions of the end-to-end distance
P′(ri) accumulated in these sampling windows are unbiased and
combined using the weighted histogram analysis method
(WHAM) method to yield the unbiased distribution P(ri)
and the associated potential of mean force.69
■ RESULTS AND DISCUSSIONS
Performance of Ligand Screening by Free Energy.
Experimentally, ligand binding to the ﬂap site was determined
using a range of techniques, including cocrystallization,
backscattering interferometry (BSI), diﬀerential scanning
ﬂuorimetry (DSF), and surface plasmon resonance (SPR).50
Among the 23 ligands studied in this work, three are
crystallographically conﬁrmed binders: 1F1, 1F1−N, and
AK2097. Binding of these fragments was also independently
conﬁrmed in BSI and DSF measurements. Eight other ligands
show a BSI-measured Kd ≤ 1 mM and/or induce a sizable
increase in the Tm of apo-PR as measured by DSF. Some of
these eight ligands also inhibit the nucleation of PR crystals.50
On the other hand, the cocrystallization with these eight ligands
proved to be unsuccessful. Here we consider these as likely
binders for the ﬂap site because of the binding signals they
present and because they can be readily docked into the
binding cavity with good shape complementarity. It should be
noted that since the binding signals from BSI and DSF do not
specify the binding site for these ligands, the possibility that
these likely ligands bind at a diﬀerent site on HIV-PR cannot be
ruled out. The 12 remaining ligands show no signal in any of
the assays and are labeled as nonbinders.
Figure 2 shows the computed binding free energies ranked
from low (favorable) to high (unfavorable) for all the ligands.
Both free energy models (BEDAM and DDM) score binders
(colored in blue in Figure 2) more favorably than the
nonbinders (red). Table 1 shows the free energies and their
uncertainties together with the information on binding from
experiments. It can be seen that all the binders and many likely
binders exhibit more favorable ΔGb0 compared with that of the
nonbinders. The average binding free energies computed by
BEDAM for these two ligand groups are −3.9 kcal/mol, and 1.4
kcal/mol, respectively. The corresponding values computed
using DDM are −2.4 and 1.3 kcal/mol. Therefore, free energy
calculations achieve a ≥ 3.7 kcal/mol binding free energy gap
separating the binders from nonbinders. No comparable
separation between the binders and nonbinders were detected
using the docking scoring function. The free energy calculations
show that the binding aﬃnities for the ﬂap site binders are weak
(i.e., in the millimolar range). This is consistent with the fact
that the binders are small fragments, with an average molecular
weight of 202 Da. In fragment library screening, compounds
with molecular weights of around 200 Da often exhibit 100 μM
to 1 mM binding aﬃnities.70 Another reason for the weak
aﬃnity is that the ﬂap site cavity is relatively exposed to the
solvent. The one ligand that stands out as the strongest ﬂap site
binder according to the DDM calculation is CS6, which has a
molecular weight of 533 Da and is signiﬁcantly larger than the
rest of the ligands. The structure of CS6 includes aromatic and
heterocyclic moieties and sulfonate and amide groups. As seen
from Table 1, CS6 is predicted by DDM to have a low
micromolar binding aﬃnity compared to the mM aﬃnity for
the three crystallographically conﬁrmed binders. There is
evidence that supports this computational prediction: the
SPR experiments (unpublished results) of ligand binding to
HIV PR suggest that CS6 binds signiﬁcantly more tightly than
the binders 1F1 and 1F1−N, in good agreement with the DDM
computed binding free energies of these molecules (Table 1).
In addition to retrospectively identifying known binders and
false positives, the calculations also provide testable predictions
Figure 2. Computed binding free energies ranked from low-to-high
from left-to-right. Upper: BEDAM; Lower: DDM.
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Table 1. BEDAM and DDM Binding Free Energies, AutoDock Scores and Experimental Information for the 23 Ligands, Unit:
kcal/mola
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for other likely binders: both BEDAM and DDM predict that
three ligands in this category h_2582690, h_02598725, and
h_3881816 bind at the ﬂap site. In addition, DDM also predicts
that CS6, h_2726205, and h_4770572 are also binders (Table
1). Experimental studies using NMR screening with site
labeling are currently underway to test these computational
predictions.
To assign binders and nonbinders, we use a cutoﬀ ΔGb0 <
−1.0 kcal/mol. This is chosen to match approximately the
weakest computed binding free energy among all three
conﬁrmed binders (AK2097, ΔGb0 = −1.4 kcal/mol, computed
by DDM). Using this criterion, we analyze the performance of
the free energy calculations in discriminating between binders
and nonbinders. The result is summarized in Table 2. BEDAM
Table 1. continued
aThe ligands shown in bold face are conﬁrmed binders and likely binders. The entries of incorrectly predicted free energies are marked in red. The
cutoﬀ in the computed ΔGb0 for separating binders and nonbinders is chosen to be ΔGb0 ≤ −1.0 kcal/mol. The error bars are estimated by comparing
the free energy results obtained from using the ﬁrst and second halves of the simulation trajectories. n/c: docking was not performed for the ligand;
the crystal structure was used in the free energy calculation. Due to the proprietary nature of the compound, the structure of CS6 has been withheld
upon request.
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and DDM calculations recovered all of the conﬁrmed binders.
Ten out of the 12 or 83.3% of the false positives are correctly
identiﬁed by the BEDAM method. The DDM calculations have
identiﬁed 91.6% the nonbinders. If we use a diﬀerent cutoﬀ,
ΔGb0 < −0.5 kcal/mol to assign the binders then the BEDAM
and DDM would still correctly identify 75% and 83.3% of the
false positives, respectively.
It is of interest to examine the correlation between results of
the two free energy methods BEDAM and DDM. The
correlation between the two sets of computed binding free
energies is given in Figure 3. It can be seen that except for the
single outlier CS6, which is a likely binder, the majority of the
points generally follow the similar trend. For CS6, its binding
aﬃnity was underestimated by the BEDAM calculation. If we
exclude this one outlier, the correlation between the results
from BEDAM and DDM is R2 = 0.56, showing reasonably good
agreement between the two methods despite the use of the
diﬀerent solvent models and force ﬁelds. It would be interesting
in future studies to compare the two approaches using exactly
the same force ﬁeld in order to better assess the potential
sources of errors.
Analysis of an Incorrectly Predicted Free Energy.
While our free energy calculations are successful overall in
distinguishing binders from false positives, there are also several
incorrect predictions (entries shown in red in Table 1). Some
of the erroneous predictions are likely to stem from limitations
of the force ﬁeld parameters for the ligands involved. One such
example is with the likely binder CS6, for which the SPR assay
shows that the molecule binds much more strongly than the
crystallographic binders 1F1 and 1F1−N (unpublished data).
This experimental result is consistent with the DDM calculated
ΔGb0 of −7.5 kcal/mol for CS6, while the BEDAM calculation
for this ligand yields an unfavorable ΔGb0 of 0.38 kcal/mol. The
CS6 molecule contains a charged sulfonate group and a
nonpolar heterocyclic moiety. It is likely that the AGBNP2
solvation parameter (used by BEDAM) for the sulfonate group
does not fully capture the desolvation penalty. In accordance
with DDM simulations in explicit solvent, the sulfonate group
of the ligand is solvated by water, but in the AGBNP2 implicit
solvent model, the sulfonate group forms an intermolecular salt
bridge between with the amine group of Lys55, which prevents
the burial of the nonpolar heterocyclic ring of the ligand inside
the binding cavity deﬁned by Pro44, Met46, and Lys55 side
chains. In addition, the AGBNP2 solvation parameter for the
sulfur atom in the heterocyclic ring was not optimized to
capture the crucial hydrophobic enclosure of this nonpolar
moiety in the binding cavity. As a result, in the BEDAM
simulated structure, the heterocyclic ring resides outside the
binding cavity, while in the DDM simulated structure it is
hydrophobically enclosed in the cavity, which signiﬁcantly
enhances the binding. We are currently working to improve the
AGBNP2 solvation parameters to optimize binding free energy
estimation.
Structural and Energetic Insights from Free Energy
Simulations. Free energy simulations not only give estimates
for the binding aﬃnities but also provide structural and
thermodynamic insights into ligand binding to the ﬂap site. For
the crystallographically conﬁrmed binders, the free energy
simulations reproduced the crystallographic binding modes
(Figure 4). In addition, the simulations predicted the binding
mode for the likely binder CS6 for which the crystal structures
are not yet available.
Figure 4 illustrates the representative binding modes for
binder 1F1 in the ﬂap site of PR observed in both the DDM
and BEDAM free energy simulations. The binding mode A
(Figure 4A), which is also found in binder AK2097, contains
three key ligand−receptor interactions: (1) the hydrophobic
indole ring is enclosed in the nonploar pocket formed by
Trp42, Pro44, Met46, and the Lys55 side chain; (2) the indole
N−H group forms a buried hydrogen bond with the Val56
backbone carbonyl oxygen; and (3) the carboxylate group in
the ligand forms an intermolecular salt bridge with Arg57. 1F1
can also bind in an alternative mode denoted mode B (Figure
4B), in which the intermolecular salt bridge between the ligand
carboxylate and Arg57 is replaced by an intramolecular salt
bridge Arg57-Glu35. The roles of the two binding modes A and
B for 1F1 binding are discussed in a later section.
The DDM free energy simulation predicted structure of the
likely binder CS6 reveals signiﬁcant diﬀerences with the binding
mode predicted by docking. The former is stabilized entirely by
nonpolar interactions: (a) the enclosure of the heterocyclic ring
Table 2. Binders and Non-Binders Correctly Identiﬁed by
Free Energy Calculations
BEDAM DDM
ligand number of correct predictions number of correct predictions
binders 3 out of 3 (100%) 3 out of 3 (100%)
nonbinders 10/12 (83.3%) 11/12 (91.6%)
Figure 3. Correspondence between the binding free energies
computed using BEDAM and DDM. Unit in kcal/mol. The ligand
CS6 is excluded from the linear regression.
Figure 4. Two binding modes observed for the binder 1F1. (A) The
dominant binding mode observed in the binders 1F1 and AK2097. (B)
An alternative binding mode adopted by 1F1. The hydrogen bonds are
shown in dotted blue.
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in the hydrophobic pocket formed by the Trp42, Pro44, Met46,
and the Lys55 side chain and (b) the nonpolar interaction
between the phenyl group in the ligand and Val56, and with the
nonpolar atoms in the side chains of Lys55 and Arg57. There
are no intermolecular hydrogen bonds in the simulation
predicted complex of CS6-PR. This is in contrast to the
docked structure, which contains several ligand−protein
intermolecular hydrogen bonds, such as the sulfonate group
in CS6 forming a salt bridge with Arg57, and the amino
carbonyl group in CS6 forming hydrogen bond with the
backbone carbonyl atom of Pro44. In the free energy
simulation, which starts from the docked structure, such
intermolecular hydrogen bonds on the protein surface become
unstable; both the sulfonate and the amino carbonyl groups in
the ligand moves away from the initial hydrogen-bonded
position and toward the solvent. This is because both the
sulfonate group and the amino carbonyl group are highly polar,
carrying very favorable solvation free energy. By design, the
docking method tries to maximize the number of ligand−
protein intermolecular interactions; in solution, however, such
interactions near the protein surface have to compete with the
solvation forces that always act to weaken solute−solute
interaction. This example with CS6 suggests that absolute
binding free energy simulations in explicit solvent (DDM)
could be used as an aid in improving scoring functions for
docking.
Role of the Diﬀerent Binding Modes. As shown in
Figure 4 and also indicated by the diﬀerent crystal structures of
HIV PR, the side chains of Arg57 and Glu35 are quite mobile
and can adopt diﬀerent orientations. In Figure 4A, the Glu35 is
solvated while Arg57 forms an intermolecular salt bridge with
the carboxylate in the ligand (binding mode A); in Figure 4B,
Arg57 forms a salt-bridge with Glu35 while the ligand
carboxylate group is solvated (binding mode B). As shown
below, our free energy simulations suggest that binding mode A
(Figure 4A) is the more dominant conformation in solution,
although both binding modes were observed in the crystal
structures of 1F1. The transition from binding mode B to the
more dominant mode A, which involves replacing the
intramolecular salt bridge Glu35-Arg57 by the intermolecular
salt bridge, has been observed in the free energy simulation of a
similar binder 1F1−N, which also carries a carboxylate group:
see Figure 5.
For ligand binding to multiple receptor conformations
grouped into macrostates, the overall equilibrium binding
constant is the weighted sum of the binding constant associated
with the binding to each of the macrostates, as long as the
macrostate conformations are deﬁned in such a way that they
include all possible conformations of the receptor.12,54 Here we
partition the receptor conformations into two macrostates A
and B, as shown in Figure 6. The binding free energy can be
expressed as
Δ = − +−Δ −ΔG kT P e P eln( )G kT G kTb A / B /A B (9)
Here PA and PB are the populations of the receptor macrostates
in the unbound state. ΔGA and ΔGB are the binding free
energies restricted to the respective receptor macrostates. To
derive eq 9, we start from the expression for the total binding
free energy, ΔGb = −kT ln(ZRL)/(ZRZL), where ZX =
∫ e− HX(r)/kTdr is the conﬁguration integral for species X (RL:
receptor−ligand complex; R and L, receptor and ligand,
respectively, free in solution.) For a receptor having two
conformational macrostates A and B, the total binding free
energy can be written as
∫ ∫
Δ = −
= −
+
= − +
− −
⎛
⎝⎜
⎞
⎠⎟
G kT
Z
Z Z
kT
e r e r
Z Z
kT
Z
Z Z
Z
Z Z
ln
ln
d d
ln
RL
R L
H r kT H r kT
P L
R L
R L
R L
R L
b
A
( )/
B
( )/RL RL
A B
(10)
Note that
= × =
= × =
−Δ
−Δ
Z
Z Z
Z
Z
Z
Z Z
P e
Z
Z Z
Z
Z
Z
Z Z
P e
R L
R L
R
R
R L
R L
G kT
R L
R L
R
R
R L
R L
G kT
A
/
B
/
A A A
A
A
B B B
B
B
(11)
where ZRA and ZRB are the conﬁguration integrals of the
unbound receptor macrostates A and B respectively, and ZR =
Figure 5. Conversion of the intramolecular salt bridge E35-R57 into
the intermolecular salt bridge between R57 and the ligand 1F1−N,
observed in the free energy simulation at λ = 1.
Figure 6. PMF along the Glu35-Arg57 distance in the apo PR
computed by umbrella sampling MD simulations in explicit solvent.
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ZRA + ZRB. Substituting eq 11 into eq 10, we obtain the overall
binding free energy as in eq 9.
An alternative approach to computing the overall binding
free energy is to use the conﬁne−release thermodynamic
cycle,30 which requires computing the potentials of mean force
(PMF) for both the apo and holo receptor. In this work, we use
eq 9 to estimate the contribution of two binding modes to the
binding free energy of 1F1, which requires the calculation of the
PMF for just the apo receptor. The unbound populations Pi
were estimated from the unbound receptor PMF computed
using umbrella sampling in which the Glu35-Arg57 distance is
the reaction coordinate. The computed PMF along this
reaction coordinate is shown in Figure 6, in which the two
basins corresponding to the conformations A and B are
separated by a free energy barrier of ∼2 kcal/mol. The
unbound receptor populations PA and PB are found to be 0.61
and 0.39, respectively. The fact that the two basins have
comparable occupancies and are separated by a moderate
barrier is consistent with the observation that the Glu35 and
Arg57 side chains are mobile and both conformations A and B
are observed in diﬀerent crystal structures.
The conditional binding free energies for each mode A and B
are computed by performing two separate free energy
simulations, in which the intramolecular distance E35-R57 is
restrained to the respective conformational basin. The resulting
binding free energies for the two binding modes are ΔGA =
−3.3 kcal/mol and ΔGb = −0.5 kcal/mol. This shows that
binding mode A, which features the intermolecular salt bridge
between Arg57-ligand, makes the dominant contribution to
ligand 1F1 binding. Substituting these values into eq 9, we
obtain the overall ΔGb0 = −3.0 kcal/mol, which is close to the
binding free energy for mode A. [The error bars in the overall
binding free energy (ΔGb0) and individual binding free energy
(ΔGA) are 0.2 kcal/mol, which is slightly smaller than their
diﬀerence.] The presence of signiﬁcant population of
conformation A separated from conformation B by an
appreciable free energy barrier in the unbound state (Figure
6) suggests that the 1F1 binding is likely to follow a
conformational selection mechanism, in which the ligand
speciﬁcally binds and stabilizes a preformed unbound
conformation of the receptor. This example also shows that
when there are multiple binding modes present, the overall
aﬃnity is usually dominated by the binding mode with the
strongest individual binding aﬃnity.
Thermodynamic Determining Factor Separating
Binders from Nonbinders. To gain a deeper understanding
of the determining factors and the thermodynamic driving
forces for binding, we examine the free energy components
ΔΔG(elec) and ΔΔG(vdw) that are associated with the
charge-decoupling and vdw-decoupling stages of the DDM
calculation, respectively (Figure 7, panels A and B). A DDM
calculation has two simulation legs, in which a ligand is
decoupled from the solvent environment and separately from
the protein binding site. In both decoupling legs, the Coulomb
intermolecular interaction is turned oﬀ ﬁrst, and then the van
der Waals intermolecular interaction is turned oﬀ. The
electrostatic component of the binding free energy
ΔΔG(elec) is the diﬀerence between the free energy of turning
oﬀ the Coulomb interaction in the solvent environment and
that in the binding site environment i.e., ΔΔG(elec) =
ΔGCoulomb(water) − ΔGCoulomb(binding_site). The van der
Waals component of the binding free energy ΔΔG(vdw) is
computed in the analogous way, ΔΔG(vdw) = ΔGvdw(water) −
ΔGvdw(binding_site). These two components generally reﬂect
the contributions from polar and nonpolar interactions to the
overall binding free energy.10 Here we note that the
decomposition of the binding free energy is path dependent;
therefore, the information drawn from such component free
energies is only qualitative, yet it can facilitate insights into
factors that promote binding. Figure 7 shows that on average,
the ΔΔG(elec) for the binders are either favorable or neutral,
while the nonbinders have signiﬁcantly more unfavorable
ΔΔG(elec). On the other hand, as seen from Figure 7, the
binders and nonbinders have a similarly large, favorable
nonpolar component ΔΔG(vdw). Indeed, while the average
ΔΔG(elec) for the binders and nonbinders are separated by a
gap of −4.7 kcal/mol (−1.8 and 2.9 kcal/mol, respectively)
favoring the binders, the diﬀerence between the average
ΔΔG(vdw) for the binders and nonbinders is only +0.6 kcal/
mol (at −4.2 and −4.8 kcal/mol, respectively), favoring the
nonbinders. The result suggests that for a ligand to bind at the
ﬂap site, it cannot have a large unfavorable electrostatic free
energy component. While nonpolar interactions drive binding
in general, for fragment binding at the ﬂap site of HIV PR, it
appears that it is the ligand−protein polar interaction that
separates binders from nonbinders.
To understand the physical origin for the electrostatic
component which distinguishes binders from nonbinders, we
examine the modeled structures of the binders and nonbinders
for clues. Most binders (except for CS6, see discussion earlier)
beneﬁt from intermolecular hydrogen bonds between the
ligand and the receptor; none of the structures of the binders
have polar atoms that are not hydrogen bonded to solute or
Figure 7. (A) Polar and (B) nonpolar components of the binding free
energy computed by DDM.
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solvent. In contrast, the simulated structures of those
nonbinders with relatively large unfavorable ΔΔG(elec)
contain partially buried polar atoms that are not hydrogen
bonded with either the receptor or the solvent. Such polar
groups suﬀer from high desolvation penalty. These unfulﬁlled
polar atoms can exist either in the ligand or in the protein.
Figure 8 shows examples of the nonbinders with large
unfavorable ΔΔG(elec). In both cases, in order to form
intermolecular hydrogen bonds with the receptor, two polar
atoms, an NH group, and/or a carboxylate oxygen are forced to
make contact with the nonpolar surface of the receptor.
As seen from Figure 7A, 1F1 and 1F1−N have the most
favorable electrostatic contributions to binding among all
binders and likely binders. This is attributable to the fact that a
carboxylate group in both of them forms a salt bridge with the
Arg57 side chain of the protease. Other binders lack such an
intermolecular salt bridge. CS6 does not form any hydrogen
bonds with the protease, and its binding was driven by
nonpolar interactions. Therefore, the favorable electrostatic
component of the binding of 1F1 and 1F1−N is due to a direct
ligand−receptor hydrogen bonding eﬀect, rather than a
desolvation eﬀect.
It is worth noting that the computed nonpolar components
ΔΔG(vdw) roughly correlate with the docking score [i.e.,
ligands with large, favorable ΔΔG(vdw) tend to have more
favorable docking score]. This suggests that while the ligand−
receptor nonpolar interaction is well-described by the scoring
function for docking, the treatment for the desolvation penalty
associated with the unfulﬁlled polar groups may be inadequate,
which has contributed to the high rate of false positives.
Insights into Ligand Optimization. The computed
binding free energies of the three crystallographically conﬁrmed
binders in this study are rather weak, which appear to explain
the lack of signiﬁcant inhibition against PR from 1F1−N in
biochemical assay, even though the binding of 1F1 and 1F1−N
were found to preferentially stabilize the closed form of HIV-
PR.50 In this work, both the free energy calculation and the SPR
measurements suggest that the likely binder CS6 exhibits a
much stronger binding aﬃnity compared to the known binders
(Table 1). The simulation predicted binding mode of CS6
revealed a possible structural basis for its stronger binding
aﬃnity. In addition to the binding cavity P1 formed by Met42,
Lys55, and Pro44, which is ﬁlled by all of the binders and also
utilized by CS6, there is an adjacent pocket P2, formed by the
side chains of Glu35, Lys55, Arg57, and Pro79. In the crystal
structures of the three binders (e.g., 1F1 and 1F1−N), the
second pocket P2 is largely unoccupied (Figure 9). In the
modeled structure of CS6, the P2 pocket is partially occupied
by a nonpolar aromatic group in the ligand. This is likely the
main reason for its exceptionally favorable nonpolar binding
free energy component ΔΔG(vdw) (see Figure 7). This
suggests that for potency enhancement, the future ligand
optimization starting from 1F1 and 1F1−N should be directed
to further exploit the second pocket P2, while preserving the
existing favorable interaction with P1 and the important
intermolecular salt bridge with Arg57. Another possible route
of optimization is to start from CS6 and add a hydrogen
bonding donor group that engages favorably with the Arg57
side chain, as in the case of 1F1 and 1F1−N.
■ CONCLUSION
The main objective of the present study is to evaluate whether
absolute binding free energy methods when applied to ligand−
protein complexes generated by docking can reduce the false
positive rate in docking. We study a set of ligands that dock
favorably to a potential allosteric site of HIV-1 protease.
Designing potent ligands that bind to this site could stabilize a
closed form of the ﬂaps of the enzyme and, when used in
combination, could potentially enhance the inhibition activity
of an active site ligand. Free energy calculations using the
binding energy distribution analysis method (BEDAM) in
implicit solvent and the double decoupling method (DDM) in
explicit solvent were performed on the 20 three top-ranked
protein−ligand complexes taken from AutoDock screening of a
library of 2518 compounds to estimate their binding aﬃnities in
solution.
The results presented in this work suggest that absolute free
energy calculations can eliminate the majority of the false
positives from a list of compounds which are top ranked by
docking and can also provide important information on the
Figure 8. Examples of nonbinders which contain partially buried, unfulﬁlled polar groups, as indicated by the white arrow in each panel. The ligand−
receptor hydrogen bonds are shown in dotted yellow.
Figure 9. Structure of bound AK2097 in the ﬂap site of PR. The
location of second pocket is indicated by the blue arrow.
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structural and thermodynamic determinants, separating binders
from nonbinders and shed light on how to improve the docking
scoring function. The study provides physical insights into
ligand optimization against the ﬂap site of PR. Indeed, the
ability to discriminate between diﬀerent thermodynamic
components and the desolvation free energy penalty, in
particular, is an essential contribution to drive drug design of
derivatives and increase eﬃciency. However, carrying out a
large number of absolute binding free energy calculations
reliably and rapidly in a semiautomated fashion still remains
very challenging, even with the tremendous increase in the
availability of computing resources.55 The automated binding
free energy workﬂow we developed based on the BEDAM
method in implicit solvent provides a promising tool in virtually
screening up to several hundreds ligands in a practical time
frame.8
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